JP2010531344A - カテプシンｋ阻害剤としての１−シアノシクロプロピル誘導体 - Google Patents

カテプシンｋ阻害剤としての１−シアノシクロプロピル誘導体 Download PDF

Info

Publication number
JP2010531344A
JP2010531344A JP2010514135A JP2010514135A JP2010531344A JP 2010531344 A JP2010531344 A JP 2010531344A JP 2010514135 A JP2010514135 A JP 2010514135A JP 2010514135 A JP2010514135 A JP 2010514135A JP 2010531344 A JP2010531344 A JP 2010531344A
Authority
JP
Japan
Prior art keywords
tetrahydro
pyrido
carbonyl
cyclohexanecarboxamide
cyanocyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010514135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531344A5 (enExample
Inventor
ドセッター，アレクサンダー・グラハム
ヘロン，ニコラ・マードック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010531344A publication Critical patent/JP2010531344A/ja
Publication of JP2010531344A5 publication Critical patent/JP2010531344A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2010514135A 2007-06-26 2008-06-24 カテプシンｋ阻害剤としての１−シアノシクロプロピル誘導体 Pending JP2010531344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94617807P 2007-06-26 2007-06-26
US4284008P 2008-04-07 2008-04-07
PCT/GB2008/050486 WO2009001129A1 (en) 2007-06-26 2008-06-24 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors

Publications (2)

Publication Number Publication Date
JP2010531344A true JP2010531344A (ja) 2010-09-24
JP2010531344A5 JP2010531344A5 (enExample) 2011-02-17

Family

ID=39761131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010514135A Pending JP2010531344A (ja) 2007-06-26 2008-06-24 カテプシンｋ阻害剤としての１−シアノシクロプロピル誘導体

Country Status (19)

Country Link
US (1) US8008279B2 (enExample)
EP (1) EP2170879B1 (enExample)
JP (1) JP2010531344A (enExample)
KR (1) KR20100039862A (enExample)
CN (1) CN101687864A (enExample)
AR (1) AR067156A1 (enExample)
AU (1) AU2008269513B2 (enExample)
BR (1) BRPI0813306A2 (enExample)
CA (1) CA2689945A1 (enExample)
CL (1) CL2008001899A1 (enExample)
CO (1) CO6251264A2 (enExample)
EC (1) ECSP109882A (enExample)
IL (1) IL202519A0 (enExample)
NZ (1) NZ581719A (enExample)
PE (1) PE20090841A1 (enExample)
RU (1) RU2470023C2 (enExample)
TW (1) TW200911806A (enExample)
UY (1) UY31180A1 (enExample)
WO (1) WO2009001129A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510932A (ja) * 2008-01-25 2011-04-07 メディベイション テクノロジーズ， インコーポレイテッド 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
JP2012512871A (ja) * 2008-12-18 2012-06-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式アザインドール
JP2014101389A (ja) * 2008-01-25 2014-06-05 Medivation Technologies Inc 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
JP2015503603A (ja) * 2012-01-11 2015-02-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ プロテアーゼ阻害剤としてのマクロ環式アミド

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
TW201018694A (en) 2008-09-29 2010-05-16 Abbott Lab Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) * 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ， インコーポレイテッド アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
WO2011049917A1 (en) * 2009-10-21 2011-04-28 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
CN104592233A (zh) 2009-12-17 2015-05-06 Abbvie公司 用于治疗神经变性和神经精神紊乱的桥头胺环稠合吲哚和二氢吲哚
WO2011084433A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-bridged ring-fused indoles and indolines
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
IN2013MN01699A (enExample) 2011-02-18 2015-06-12 Medivation Technologies Inc
CN103086923B (zh) * 2013-01-21 2014-04-23 吉林大学 肼腈类组织蛋白酶k抑制剂及其在治疗骨质疏松症方面的应用
CA2923272A1 (en) * 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2016027285A2 (en) * 2014-08-22 2016-02-25 Alkem Laboratories Ltd. Bicyclic heteroaryl amides as cathepsin cysteine protease inhibitors
CN105837479B (zh) * 2016-04-05 2017-10-27 吉林大学 肼腈类组织蛋白酶k抑制剂及其在制备治疗骨关节炎药物中的应用
EP3600451A4 (en) * 2017-03-29 2021-04-14 Minerva Biotechnologies Corporation MEANS FOR STEM CELL DIFFERENTIATION AND CANCER TREATMENT
EP4467544A1 (en) * 2022-01-21 2024-11-27 Shandong New Time Pharmaceutical Co., Ltd. Cathepsin k inhibitor, and preparation method therefor and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506364A (ja) * 1999-07-30 2003-02-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼインヒビターとして有益な新規スクシネート誘導体化合物
JP2003525874A (ja) * 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
JP2005517640A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
JP2005533805A (ja) * 2002-06-24 2005-11-10 アストラゼネカ・アクチエボラーグ 新規化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068645A2 (en) 2000-03-15 2001-09-20 Axys Pharmaceuticals, Inc. N-cyanomethylcarboxamides and their use as protease inhibitors
WO2002069901A2 (en) 2001-03-02 2002-09-12 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
RU2278863C2 (ru) * 2001-08-10 2006-06-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция и способ ингибирования активности катепсина s
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
US7109339B2 (en) 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506364A (ja) * 1999-07-30 2003-02-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼインヒビターとして有益な新規スクシネート誘導体化合物
JP2003525874A (ja) * 2000-01-06 2003-09-02 メルク フロスト カナダ アンド カンパニー プロテアーゼ阻害剤としての新規化合物および組成物
JP2005517640A (ja) * 2001-12-04 2005-06-16 エフ．ホフマン−ラ　ロシュ　アーゲー 置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用
JP2005533805A (ja) * 2002-06-24 2005-11-10 アストラゼネカ・アクチエボラーグ 新規化合物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510932A (ja) * 2008-01-25 2011-04-07 メディベイション テクノロジーズ， インコーポレイテッド 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
JP2014101389A (ja) * 2008-01-25 2014-06-05 Medivation Technologies Inc 新規２，３，４，５−テトラヒドロ−１Ｈ−ピリド［４，３−ｂ］インドール化合物およびその使用方法
US9115137B2 (en) 2008-01-25 2015-08-25 Medivation Technologies, Inc. 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof
JP2012512871A (ja) * 2008-12-18 2012-06-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式アザインドール
JP2015503603A (ja) * 2012-01-11 2015-02-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ プロテアーゼ阻害剤としてのマクロ環式アミド

Also Published As

Publication number Publication date
US20090012077A1 (en) 2009-01-08
NZ581719A (en) 2011-08-26
AU2008269513A1 (en) 2008-12-31
WO2009001129A9 (en) 2010-02-04
EP2170879A1 (en) 2010-04-07
CA2689945A1 (en) 2008-12-31
IL202519A0 (en) 2010-06-30
WO2009001129A1 (en) 2008-12-31
RU2010101279A (ru) 2011-08-10
UY31180A1 (es) 2009-01-30
CN101687864A (zh) 2010-03-31
CL2008001899A1 (es) 2009-07-17
RU2470023C2 (ru) 2012-12-20
AR067156A1 (es) 2009-09-30
KR20100039862A (ko) 2010-04-16
ECSP109882A (es) 2010-02-26
EP2170879B1 (en) 2013-01-16
BRPI0813306A2 (pt) 2017-05-16
PE20090841A1 (es) 2009-08-02
TW200911806A (en) 2009-03-16
CO6251264A2 (es) 2011-02-21
AU2008269513B2 (en) 2011-06-16
US8008279B2 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
JP2010531344A (ja) カテプシンｋ阻害剤としての１−シアノシクロプロピル誘導体
ES2930585T3 (es) Inhibidores de TYK2 y usos de los mismos
TWI478714B (zh) 作為Ｊａｎｕｓ激酶３（ＪＡＫ３）抑制劑之含氮雜芳基衍生物類
ES2368013T3 (es) Derivados de hidantoína usados como inhibidores de mmp.
KR20080043396A (ko) 신규 디아자스피로알칸 및 ｃｃｒ８ 매개성 질환의 치료를위한 그의 용도
JP2022522534A (ja) Ｐｒｍｔ５を標的にする化合物
KR20100039326A (ko) 신규 화합물 ９５１： ｃｒｔｈ２ 조절자로서 비페닐옥시프로판산 및 중간체
JP2023076560A (ja) Ｃｏｔモジュレーター及びその使用方法
ES2732437T3 (es) Moduladores del receptor de CXCR7
EP3484876A1 (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
CN113330014B (zh) 抑制mnk1和mnk2的多环化合物
KR20120056838A (ko) 스피로시클릭 아미드 유도체
US20230113609A1 (en) Sstr5 antagonists
JP2009500405A (ja) 炎症性および免疫疾患の処置のためのｐｄｅ４阻害剤としてのピリドピリミジン誘導体
WO2024078581A1 (en) Selective bcl-xl protac compounds and uses thereof
CN120752240A (zh) 作为eIF4E抑制剂的化合物和组合物及其用途
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
JP2009510159A (ja) 喘息および慢性閉塞性肺疾患の処置のための新規５，６−ジヒドロピラゾロ［３，４−ｅ］［１，４］ジアゼピン−４（１Ｈ）−オン誘導体
WO2009001128A1 (en) 1,2-cycl0hexane dicarboxamides as cathepsin inhibitors
WO2022189387A1 (en) Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors
WO2024200835A1 (en) Novel mettl3 inhibitors and use thereof in therapy
SA08290382B1 (ar) مشتقات 1- سيانوسيكو بروبيل متضمنة نظام حلقة ثلاثي حلقي وإستخدامها في العلاج
WO2024073475A1 (en) Cereblon ligands and uses thereof
EA048052B1 (ru) ПРОИЗВОДНЫЕ N-(ИМИДАЗО[1,2-b]ПИРИДАЗИН-3-ИЛ)-1-ЦИКЛОГЕКСИЛ-2H-ИНДАЗОЛ-5-КАРБОКСАМИДА И N-(ПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-ИЛ)-1-ЦИКЛОГЕКСИЛ-2H-ИНДАЗОЛ-5-КАРБОКСАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IRAK4 ДЛЯ ЛЕЧЕНИЯ АСТМЫ
WO2021147790A1 (zh) 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131216